Satellite Banner
Technology Networks Header
Friday, August 29, 2014
Technology Networks
 
Register | Sign in
Home Page>Products
  Product News
Crown Bioscience to Showcase Novel “in life” Platforms for Oncology
Tuesday, February 11, 2014
Company will highlight its expertise in Oncology Drug Discovery at AACR 2014.

GenomOncology To Enable CompanionDxTM Clinical Cancer Panels
Monday, February 10, 2014
The GO Clinical WorkbenchTM is selected to launch a series of next generation sequencing (NGS)-based assays.

Horizon Discovery Launches GENASSIST Line of Kits and Reagents for Gene-Editing, utilizing CRISPR Technology
Monday, February 10, 2014
The first products and services from GENASSIST™ enable easier, robust implementation of CRISPR and rAAV gene editing experiments.

Fluxion Biosciences Expands IsoFlux Discovery Services Capabilities with Clinical Sample Procurement
Monday, February 10, 2014
New capability provides a full-service option for circulating tumor cell studies.

Exiqon Releases New Online Search Tool for Gene Expression Studies
Thursday, February 06, 2014
New version of miRSearch for rapid retrieval of detailed information about microRNA.

University of Pittsburgh Selects GenomOncology
Wednesday, February 05, 2014
Company’s GenomAnalytics™ platform and services selected to support research efforts.

First RayStation® Order in the United Kingdom
Saturday, February 01, 2014
Ninewells to be the first clinical installation of RayStation® in the United Kingdom.

Ready-to-Use Lentivirus for miRNA Expression and Inhibition
Saturday, February 01, 2014
AMSBIO’s anti-miRNA lentivirus are produced from the optimally designed anti miRNA lentivectors.

Almac Announces the Presentation of External Validation of ColDx Signature
Friday, January 31, 2014
Data presented supporting Almac developed colon signature as a significant predictor of risk of recurrence in stage II colon cancer.

<< 4 5 6 7 8 9 10 >>
Showing Results 61 - 70 of 647
Scientific News
Dutch Public-Private Partnership Invests 28 Million Euro on Research into Personalized Medicine
The Netherlands' three Top Institutes for life-science research announce a joint research target to bring personalized medicine closer to reality.
FDA Grants Orphan Drug Status for Quark's QPI-1002 for the Prophylaxis of DGF in Kidney Transplant Patients
Company completes enrollment and dosing in the dose-escalation safety portion of a Phase 1/2 study.
Oncolytics Biotech® Receives MHRA Approval to Conduct Phase 3 Trial for REOLYSIN®
Conducting the trials in U.S. and Europe will allow Company to access the physicians that have worked with REOLYSIN in head and neck cancers.
Shenogen and Chemizon Announce Drug Discovery Collaboration Focused on Oncology and Endocrine Disorders
The agreement will create small molecule therapeutics targeting modulators of the ER-alpha 36 receptor.
Dutch Public-Private Partnership Invests 28 Million Euro on Research into Personalized Medicine
The Netherlands' three Top Institutes for life-science research announce a joint research target to bring personalized medicine closer to reality.
FDA Grants Orphan Drug Status for Quark's QPI-1002 for the Prophylaxis of DGF in Kidney Transplant Patients
Company completes enrollment and dosing in the dose-escalation safety portion of a Phase 1/2 study.
Oncolytics Biotech® Receives MHRA Approval to Conduct Phase 3 Trial for REOLYSIN®
Conducting the trials in U.S. and Europe will allow Company to access the physicians that have worked with REOLYSIN in head and neck cancers.
Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv